Post Profile






The most respected medical journal in the US just eviscerated a drug that's cost taxpayers over $1 billion (MNK)

A new study published by JAMA Internal Medicine — poses a really important question to lawmakers and taxpayers alike. Over the last five years, why has the US government spent $1 billion dollars for a drug that is no more effective than alternatives that are tens of thousands of dollars cheaper? The drug is called Acthar, and for the past year it has been the focus of a study by the Oregon Health and Science University School of Medicine and Oregon State, that has been trying to understand why doctors keep prescribing it for ailments that it has never been proven to treat effectively.
read more

share

Related Posts


Study Examines Expedited FDA Drug Approvals, Safety Questions Remain

Health : Newswise Medical News

Fewer patients were studied as part of expedited reviews of new drugs approved by the U.S. Food and Drug Administration (FDA) in 2008 and some safety questions remain unanswered, according to a study published by JAMA Internal Medic...

New UMMS study shows how to account for social disparities in health care costs

Health : EurekAlert: Health

(University of Massachusetts Medical School) In a new study published in JAMA Internal Medicine, Arlene Ash, PhD, recommends allocating some health insurance dollars for patients in vulnerable communities and for those subject to so...

Results of Medication Studies in Journals May be Misleading

Health : Newswise Medical News

Studies about medications published in the most influential medical journals are frequently designed in a way that yields misleading or confusing results. The journals are the NEJM, JAMA, The Lancet, Annals of Internal Medicine, the...

Five studies in JAMA, JAMA Internal Medicine examine effect of testosterone treatment on various health outcomes in men

Health : EurekAlert: Health

(The JAMA Network Journals) Five new JAMA and JAMA Internal Medicine studies published online compare a variety of health outcomes in men with low testosterone who used testosterone.

Comments


Copyright © 2016 Regator, LLC